ESCAPE Bio is a preclinical stage biopharmaceutical company focused on the discovery and development of therapies to treat genetically defined, neurodegenerative diseases. We are passionate about making a meaningful clinical impact for patients suffering from CNS diseases and believe in a genetically defined approach to achieving this goal.
Location: United States, California, South San Francisco
Employees: 11-50
Total raised: $73M
Founded date: 2015
Investors 2
| Date | Name | Website |
| - | OrbiMed | orbimed.co... |
| - | New Leaf V... | nlvpartner... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 14.09.2020 | - | $73M | - |
Mentions in press and media 5
| Date | Title | Description |
| 14.09.2020 | ESCAPE Bio Closes $73 Million in Crossover Financing | SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--ESCAPE Bio, a clinical stage company developing novel, precisely targeted therapeutics for genetic neurodegenerative diseases, today announced the closing of a $73M financing led by Wellington M... |
| 14.09.2020 | Escape Bio nabs $73M as race with well-heeled Biogen and Denali heats up | Escape Bio has drifted from the focus that earned it a $63 million Series A in 2017, but that hasn’t hindered the company’s ability to raise cash from bluechip investors. In what was publicly billed as a crossover round, the neu... |
| 14.09.2020 | ESCAPE BIO CLOSES $73 MILLION IN CROSSOVER FINANCING TO ADVANCE CLINICAL DEVELOPMENT OF PRECISION NEUROLOGY MEDICINES FOR GENETIC NEURODEGENERATION – ESCAPE BIO | - |
| 14.09.2020 | ESCAPE Bio Closes $73 Million in Crossover Financing to Advance Clinical Development of Precision Neurology Medicines for Genetic Neurodegeneration | - |
| 14.09.2020 | ESCAPE Bio Closes $73M in Crossover Financing | SOUTH SAN FRANCISCO, CA, ESCAPE Bio announced the closing of a $73M financing led by Wellington Management Company. >> Click here for more funding data on ESCAPE Bio >> To export ESCAPE Bio funding data to PDF and Excel, cli... |